Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

FEMY vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
FEMY
Femasys Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$13M
5Y Perf.-94.5%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$55.53B
5Y Perf.+4.6%

FEMY vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
FEMY logoFEMY
BDX logoBDX
IndustryMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$13M$55.53B
Revenue (TTM)$2M$21.36B
Net Income (TTM)$-19M$1.14B
Gross Margin62.0%46.5%
Operating Margin-7.7%10.6%
Forward P/E12.3x
Total Debt$5M$19.18B
Cash & Equiv.$9M$851M

FEMY vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

FEMY
BDX
StockJun 21May 26Return
Femasys Inc. (FEMY)1005.5-94.5%
Becton, Dickinson a… (BDX)100104.6+4.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: FEMY vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BDX leads in 5 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Femasys Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
FEMY
Femasys Inc.
The Growth Play

FEMY is the clearest fit if your priority is growth exposure.

  • Rev growth 40.8%, EPS growth 44.0%, 3Y rev CAGR 23.9%
  • 40.8% revenue growth vs BDX's 8.2%
Best for: growth exposure
BDX
Becton, Dickinson and Company
The Income Pick

BDX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 1 yrs, beta 0.66, yield 2.7%
  • 80.2% 10Y total return vs FEMY's -96.3%
  • Lower volatility, beta 0.66, Low D/E 75.5%, current ratio 1.11x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthFEMY logoFEMY40.8% revenue growth vs BDX's 8.2%
Quality / MarginsBDX logoBDX5.3% margin vs FEMY's -8.1%
Stability / SafetyBDX logoBDXBeta 0.66 vs FEMY's 1.10, lower leverage
DividendsBDX logoBDX2.7% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)BDX logoBDX+51.8% vs FEMY's -60.6%
Efficiency (ROA)BDX logoBDX2.1% ROA vs FEMY's -116.3%, ROIC 4.3% vs -347.4%

FEMY vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

FEMYFemasys Inc.

Segment breakdown not available.

BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

FEMY vs BDX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBDXLAGGINGFEMY

Income & Cash Flow (Last 12 Months)

Evenly matched — FEMY and BDX each lead in 3 of 6 comparable metrics.

BDX is the larger business by revenue, generating $21.4B annually — 9316.2x FEMY's $2M. BDX is the more profitable business, keeping 5.3% of every revenue dollar as net income compared to FEMY's -8.1%. On growth, FEMY holds the edge at +39.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricFEMY logoFEMYFemasys Inc.BDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$2M$21.4B
EBITDAEarnings before interest/tax-$17M$4.2B
Net IncomeAfter-tax profit-$19M$1.1B
Free Cash FlowCash after capex-$19M$3.1B
Gross MarginGross profit ÷ Revenue+62.0%+46.5%
Operating MarginEBIT ÷ Revenue-7.7%+10.6%
Net MarginNet income ÷ Revenue-8.1%+5.3%
FCF MarginFCF ÷ Revenue-8.4%+14.7%
Rev. Growth (YoY)Latest quarter vs prior year+39.9%-10.6%
EPS Growth (YoY)Latest quarter vs prior year+69.9%-2.0%
Evenly matched — FEMY and BDX each lead in 3 of 6 comparable metrics.

Valuation Metrics

BDX leads this category, winning 2 of 3 comparable metrics.
MetricFEMY logoFEMYFemasys Inc.BDX logoBDXBecton, Dickinson…
Market CapShares × price$13M$55.5B
Enterprise ValueMkt cap + debt − cash$9M$73.9B
Trailing P/EPrice ÷ TTM EPS-0.96x26.29x
Forward P/EPrice ÷ next-FY EPS est.12.27x
PEG RatioP/E ÷ EPS growth rate1.59x
EV / EBITDAEnterprise value multiple14.65x
Price / SalesMarket cap ÷ Revenue5.77x2.54x
Price / BookPrice ÷ Book value/share3.03x1.73x
Price / FCFMarket cap ÷ FCF20.80x
BDX leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

BDX leads this category, winning 7 of 9 comparable metrics.

BDX delivers a 4.5% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-5 for FEMY. BDX carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to FEMY's 0.80x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs FEMY's 2/9, reflecting strong financial health.

MetricFEMY logoFEMYFemasys Inc.BDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity-5.3%+4.5%
ROA (TTM)Return on assets-116.3%+2.1%
ROICReturn on invested capital-3.5%+4.3%
ROCEReturn on capital employed-167.9%+5.4%
Piotroski ScoreFundamental quality 0–927
Debt / EquityFinancial leverage0.80x0.76x
Net DebtTotal debt minus cash-$5M$18.3B
Cash & Equiv.Liquid assets$9M$851M
Total DebtShort + long-term debt$5M$19.2B
Interest CoverageEBIT ÷ Interest expense-8.85x4.09x
BDX leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

BDX leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in BDX five years ago would be worth $11,693 today (with dividends reinvested), compared to $374 for FEMY. Over the past 12 months, BDX leads with a +51.8% total return vs FEMY's -60.6%. The 3-year compound annual growth rate (CAGR) favors BDX at 1.6% vs FEMY's -15.7% — a key indicator of consistent wealth creation.

MetricFEMY logoFEMYFemasys Inc.BDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date-29.5%+0.7%
1-Year ReturnPast 12 months-60.6%+51.8%
3-Year ReturnCumulative with dividends-40.1%+5.0%
5-Year ReturnCumulative with dividends-96.3%+16.9%
10-Year ReturnCumulative with dividends-96.3%+80.2%
CAGR (3Y)Annualised 3-year return-15.7%+1.6%
BDX leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

BDX leads this category, winning 2 of 2 comparable metrics.

BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than FEMY's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BDX currently trades 74.6% from its 52-week high vs FEMY's 38.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricFEMY logoFEMYFemasys Inc.BDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5001.10x0.66x
52-Week HighHighest price in past year$1.16$205.52
52-Week LowLowest price in past year$0.31$100.31
% of 52W HighCurrent price vs 52-week peak+38.7%+74.6%
RSI (14)Momentum oscillator 0–10057.332.2
Avg Volume (50D)Average daily shares traded513K2.5M
BDX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.

MetricFEMY logoFEMYFemasys Inc.BDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$172.85
# AnalystsCovering analysts33
Dividend YieldAnnual dividend ÷ price+2.7%
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS$4.17
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.8%
Insufficient data to determine a leader in this category.
Key Takeaway

BDX leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.

Best OverallBecton, Dickinson and Compa… (BDX)Leads 4 of 6 categories
Loading custom metrics...

FEMY vs BDX: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is FEMY or BDX a better buy right now?

For growth investors, Femasys Inc.

(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus 8. 2% for Becton, Dickinson and Company (BDX). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — FEMY or BDX?

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.

9%, compared to -96. 3% for Femasys Inc. (FEMY). Over 10 years, the gap is even starker: BDX returned +80. 2% versus FEMY's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — FEMY or BDX?

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Femasys Inc. 's 1. 10β — meaning FEMY is approximately 68% more volatile than BDX relative to the S&P 500. On balance sheet safety, Becton, Dickinson and Company (BDX) carries a lower debt/equity ratio of 76% versus 80% for Femasys Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — FEMY or BDX?

By revenue growth (latest reported year), Femasys Inc.

(FEMY) is pulling ahead at 40. 8% versus 8. 2% for Becton, Dickinson and Company (BDX). On earnings-per-share growth, the picture is similar: Femasys Inc. grew EPS 44. 0% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — FEMY or BDX?

Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.

7% net margin versus -812. 3% for Femasys Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — FEMY leads at 62. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — FEMY or BDX?

In this comparison, BDX (2.

7% yield) pays a dividend. FEMY does not pay a meaningful dividend and should not be held primarily for income.

07

Is FEMY or BDX better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, FEMY: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between FEMY and BDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FEMY is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while FEMY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

FEMY

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 37%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.0%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform FEMY and BDX on the metrics below

Revenue Growth>
%
(FEMY: 39.9% · BDX: -10.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.